[Target therapy by monoclonal antibody against ovarian carcinoma conjugated with liposome and adriamycin].
Conjugates of monoclonal antibody (MAb) and adriamycin entrapped in liposome (MLA) were prepared by COC166-9. The MAb against ovarian serous adenocarcinoma was generated in our laboratory. Target therapies were done in nude mice model with subcutaneous tumor xenografts in 24 and ascitic carcinoma in 16 by MLA. The results demonstrated that MLA group presented the best therapeutic effect than all the other groups, which gave a very helpful clue to clinical target therapy of ovarian carcinoma in the future.
Beijing Medical University People's Hospital Gynecology Oncology Research Laboratory.
W J
WJ
Li
H N
HN
Qian
W Y
WY
Lu
D000818:Animals; D000911:Antibodies, Monoclonal; D004317:Doxorubicin / Q000008:administration & dosage*; D004337:Drug Carriers; D005260:Female; D000922:Immunotoxins / Q000627:therapeutic use*; D008081:Liposomes; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D004337:Drug Carriers; D000922:Immunotoxins; D008081:Liposomes; D004317:Doxorubicin